EUVIMEDEUVIMED entdecken
Crossref

Impact of Semaglutide on Cardiovascular Risk ― Investigation of the Japanese Population in the SELECT Trial ―

Issei Komuro, Tomoyuki Nishida, Tomoko Takano, Kohjiro Ueki, Shogo Wada, Koichi Node

Circulation Journal · 21.11.2026

DOI: 10.1253/circj.cj-26-0448 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Circulation Journal, erschienen am 21.11.2026. Verfasst von Issei Komuro und 5 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In the international SELECT trial (NCT03574597), the glucagon-like peptide-1 receptor agonist semaglutide reduced the risk of major adverse cardiovascular events (MACE) by 20% vs. placebo in individuals with overweight/obesity (body mass index ≥27 kg/m2) without diabetes. This exploratory subgroup analysis of the SELECT dataset investigated the effect of semaglutide on cardiovascular outcomes in Japanese individuals (Japanese population) and an indication population meeting Japanese criteria for subcutaneous semaglutide 2.4 mg for the treatment of obesity.Methods and Results: Participants were randomly allocated to once-weekly subcutaneous semaglutide 2.4 mg or placebo, alongside standard of care. The primary cardiovascular endpoint was time to first event adjudication committee-confirmed MACE. There were 357 participants (semaglutide, n=177; placebo, n=180) in the Japanese population and 15,903 (semaglutide, n=7,963; placebo, n=7,940) in the indication population. In the Japanese population, MACE were observed in 10 and 16 participants in the semaglutide and placebo groups, respectively (hazard ratio 0.61; 95% confidence interval 0.27–1.32), directionally consistent with the SELECT population. MACE risk reduction in the indication population followed a similar trend. Changes in secondary cardiovascular and metabolic outcomes favored semaglutide over placebo in both populations. Safety outcomes were consistent with the SELECT population.

Conclusions

In this exploratory, hypothesis-generating analysis of Japanese individuals and those meeting Japanese criteria for semaglutide administration, semaglutide’s effects on cardiovascular outcomes were directionally consistent with those reported in the overall SELECT population.

Zitieren

APA

Komuro, I., Nishida, T., Takano, T., Ueki, K., Wada, S., & Node, K. (2026). Impact of Semaglutide on Cardiovascular Risk ― Investigation of the Japanese Population in the SELECT Trial ―. Circulation Journal. https://doi.org/10.1253/circj.cj-26-0448

Vancouver

Komuro I, Nishida T, Takano T, Ueki K, Wada S, Node K. Impact of Semaglutide on Cardiovascular Risk ― Investigation of the Japanese Population in the SELECT Trial ―. Circulation Journal. 2026. doi:10.1253/circj.cj-26-0448

BibTeX
@article{Komuro2026,
  author = {Komuro, Issei and Nishida, Tomoyuki and Takano, Tomoko and Ueki, Kohjiro and Wada, Shogo and Node, Koichi},
  title = {Impact of Semaglutide on Cardiovascular Risk ― Investigation of the Japanese Population in the SELECT Trial ―},
  journal = {Circulation Journal},
  year = {2026},
  doi = {10.1253/circj.cj-26-0448}
}
Kostenlos starten →